Azienda Ospedaliero Universitaria Maggiore della Carita
maggioreosp.novara.itTotal trials
53
Active
11
Phase 3
4
Total enrollment
21,007
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| molecular investigation | — | — | — | — | — | 1 |
Next readouts
- 2024-12
Top conditions
- Obesity, Childhood4
- Obesity4
- Coronary Artery Disease3
- Myocardial Infarction3
- Surgery2
- Pediatric Obesity2
- Diabetes Mellitus, Type 22
- Artificial Respiration1
Frequently asked questions about Azienda Ospedaliero Universitaria Maggiore della Carita
- How many clinical trials does Azienda Ospedaliero Universitaria Maggiore della Carita have on ClinicalTrials.gov?
- Azienda Ospedaliero Universitaria Maggiore della Carita is listed as the lead sponsor on 53 clinical trials in ClinicalTrials.gov, 11 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Azienda Ospedaliero Universitaria Maggiore della Carita's trials are in Phase 3?
- 4 of Azienda Ospedaliero Universitaria Maggiore della Carita's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Azienda Ospedaliero Universitaria Maggiore della Carita focus on?
- Azienda Ospedaliero Universitaria Maggiore della Carita's most-studied conditions on ClinicalTrials.gov are Obesity, Childhood, Obesity, Coronary Artery Disease, Myocardial Infarction, Surgery.
- When are Azienda Ospedaliero Universitaria Maggiore della Carita's next clinical trial readouts?
- Azienda Ospedaliero Universitaria Maggiore della Carita has 1 upcoming primary-completion readout tracked here; the soonest is “European Active Surveillance of Renal Cell Carcinoma Study (EASE RCC Study)”, expected around 2024-12.